ClinicalTrials.gg
Active, not recruitingNCT07185295POLYPHEMUpdated Nov 24, 2025

Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy

A Phase 4 interventional study of To maintain anticoagulant therapy during the polypectomy of colorectal lesions in Anticoagulated Patients, sponsored by Outcomes'10. Active, not recruiting at 10 sites in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Outcomes'10 · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2024, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
481
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Hemorrhage with a site in Spain — 10 open to participants now, 15 under way, 5 of them phase 3. Hemorrhage · Spain.

Planned enrollment
13th of 39
481 · median 188
Started
2024
with 2 others
Phase 4
10 of 53
4 open now
Primary completion
2026-11
later than 4 of 14 live
Registered
51st of 53
by date

Among the 53 studies in Hemorrhage with a site in Spain, this one is the 13th largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 in phase 4, reaches primary completion later than 4 of the 14 other live ones, and was the 51st registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

10 of the 53 studies in Hemorrhage with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Hemorrhage with a site in Spain, or all of them as a file.
02

Study summary

This study is designed to find out if it is safe to keep taking blood-thinning medicine during the removal of polyps from the colon or rectum.

It includes patients who regularly take blood thinners and need an elective colonoscopy.

The main goal is to see how often patients have serious bleeding after the polyp removal within 30 days.

The study is being done in several hospitals, and doctors evaluating the results do not know which treatment patients receive.

Read the detailed description

This multicenter, phase IV, assessor-blinded, non-inferiority clinical trial evaluates the safety of maintaining oral anticoagulant therapy during colorectal polypectomy. The study population includes patients receiving chronic oral anticoagulation treatment with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) who are scheduled for elective colonoscopy for any indication.

The primary objective is to assess the incidence of clinically significant post-polypectomy bleeding within 30 days after the procedure. The trial tests the hypothesis that continuing anticoagulant therapy during polypectomy is non-inferior to interrupting it, with a non-inferiority margin set at 10%.

A total of 481 patients will be enrolled, with 241 patients per group. The intervention consists of maintaining ongoing anticoagulant treatment without modification before the procedure. This trial is classified as a low-intervention study according to regulatory guidelines and aims to provide evidence to optimize the management of anticoagulated patients undergoing colorectal polypectomy.

03

Conditions studied

  • Anticoagulated Patients

Browse trials for

Keywords

  • Anticoagulant therapy
  • colorectal polypectomy
  • Oral anticoagulants
  • colonoscopy
  • Hemorrhage
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18 years.
  • Patients scheduled for elective outpatient colonoscopy for any indication, in whom removal of colorectal polyps will be performed if identified during the procedure.
  • Anticoagulant treatment with vitamin K antagonists (acenocoumarol or warfarin) or direct oral anticoagulants (dabigatran, edoxaban, apixaban, or rivaroxaban) prior to the colonoscopy.

Exclusion criteria

Exclusion Criteria:

  • Concomitant antiplatelet therapy.

Age over 85 years.

Urgent colonoscopy.

Labile (time in therapeutic range less than 60%) documented in the previous 3 months in patients receiving VKAs.

Supratherapeutic INR (>3.5) at the time of the procedure in patients on VKAs.

Pregnancy.

Decompensated liver cirrhosis.

Inability, at the investigator's discretion, to understand the periprocedural anticoagulation regimen.

Known coagulopathy or bleeding diathesis, including count \<50,000/µl in the previous 12 months.

Scheduled endoscopic dilation.

Severe psychiatric disorder.

Removal of colorectal lesions by endoscopic submucosal dissection.

Previous diagnosis of renal failure defined as creatinine >2 mg/dl or clearance \<30 ml/min.

Planned high bleeding risk procedure during simultaneous gastroscopy.

Previous inclusion in the trial. Patients may only be included once.

Patients who are not candidates for a second endoscopic intervention due to clinical conditions.

Any clinical situation or concomitant treatment that, in the investigator's opinion, poses a significant bleeding risk.

Patients with polyps larger than 4 cm pending endoscopic resection.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
481 participants (estimated)

Study arms

  • Experimental
    Maintained Anticoagulant Therapy

    Patients in this treatment group will continue their anticoagulant therapy during the procedure. For those on vitamin K antagonists (VKAs), INR levels will be checked 7-14 days before the endoscopy, and doses adjusted if necessary to maintain therapeutic range (\<3.5) before the procedure. Patients on direct oral anticoagulants (DOACs) will skip only the morning dose on the day of the procedure without other changes.

    Procedure: To maintain anticoagulant therapy during the polypectomy of colorectal lesions

  • No intervention
    Discontinued Anticoagulant Therapy

    In patients assigned to this treatment arm, anticoagulation will be temporarily discontinued following the recommendations of the 2021 BSG-ESGE clinical practice guideline. The distinction between high and low thrombotic risk will be made according to guidelines.

Interventions

  • ProcedureTo maintain anticoagulant therapy during the polypectomy of colorectal lesions

    Group A

06

What researchers measure

Primary outcomes

  1. Clinically significant intraprocedural bleeding

    Major bleeding during colonoscopy that requires procedure interruption, a drop in hemoglobin \>2 g/dL, blood transfusion, interventional radiology, hospitalization, surgery, or results in death. The following data will be collected for bleeding events: * Date of the event. * Length of hospital stay: Quantitative nominal variable. Unit: days. * ICU admission: Binary variable (Yes/No). * Severity: Assessed according to the ASGE classification.

    Time frame: 1 month

  2. Clinically significant delayed hemorrhage

    Gastrointestinal bleeding occurring within 30 days after completion of the colonoscopy that requires an emergency visit, hospitalization, or an intervention. Date of the event. - Length of hospital stay: Quantitative nominal variable. Unit: days. - ICU admission: Binary variable (Yes/No). - Severity: Assessed according to the ASGE classification.

    Time frame: 1 month

Secondary outcomes

  1. Acute Myocardial Infarction

    A clinical syndrome characterized by evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Data collected will include event date, hospital stay duration, and ICU stay duration.

    Time frame: 1 month

  2. Hospitalization for Unstable Angina

    Unscheduled hospitalization for the treatment of unstable angina occurring within 24 hours from symptom onset. Hospitalization is defined as admission to an inpatient unit or an emergency department visit resulting in a stay of at least 24 hours. Data collected will include event date, hospital stay duration, and ICU stay duration.

    Time frame: 1 month

  3. Deep Vein Thrombosis

    Any deep vein thrombosis diagnosed in the upper body (internal jugular, subclavian, axillary/brachial) or lower extremities (iliac, femoral/popliteal, gastrocnemius, peroneal, posterior tibial), or in the inferior vena cava or deep splanchnic veins, as confirmed by ultrasound or contrast imaging techniques including computed tomography (CT), angiography, or magnetic resonance imaging (MRI). Data collected will include event date, hospital stay duration, and ICU stay duration.

    Time frame: 1 month

  4. Pulmonary Embolism

    Any pulmonary embolism diagnosed by computed tomography (CT), ventilation-perfusion (V/Q) scan, invasive pulmonary angiography, echocardiography (thrombus visualized in the main pulmonary artery), or confirmed by autopsy. Data collected will include event date, hospital stay duration, and ICU stay duration.

    Time frame: 1 month

  5. Stroke, Including Transient Ischemic Attack

    Stroke is defined as an acute episode of focal or global neurological dysfunction caused by a cerebral, spinal, or retinal vascular injury as a result of hemorrhage or infarction. Transient ischemic attack (TIA) is defined as a temporary (\< 24 hours) episode of focal neurological dysfunction caused by cerebral, spinal, or retinal ischemia without acute infarction. Data collected will include event date, hospital stay duration, and ICU stay duration.

    Time frame: 1 month

  6. Peripheral Arterial Embolism or Thrombosis

    Any embolism or arterial thrombosis diagnosed by computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) involving the splanchnic circulation, upper or lower extremities, or renal arteries. Data collected will include event date, type, hospital stay duration, and ICU stay duration.

    Time frame: 1 month

  7. Clinically non-significant intraprocedural bleeding

    Bleeding that persists for more than 1 minute, requires endoscopic treatment, and does not meet the criteria for clinically significant intraprocedural bleeding.

    Time frame: 1 month

  8. Death

    It will be recorded as a nominal categorical variable: \- No/death If death is selected: Cause/unknown cause. It will be also recorded the date of death

    Time frame: 1 month

07

Study locations

10 sites
  • Clínica Rotger Quirónsalud
    Palma, Balearic Islands 07012, Spain
  • Servicio de Aparato Digestivo. Hospital Sierrallana. Barrio Ganzo,
    Torrelavega, Cantabria 39300, Spain
  • Servicio de Gastroenterología y Hepatología. Hospital Universitario Río Hortega.
    Valladolid, Castille and León 47012, Spain
  • Servicio de Digestología, Hospital del Mar. Instituto Hospital del Mar de Investigaciones Médicas.
    Barcelona, Catalonia 08003, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Catalonia 08036, Spain
  • Servicio de Gastroenterología. Hospital Universitario Príncipe de Asturias. Madrid.
    Alcalá de Henares, Madrid 28805, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid, Spain
  • Servicio de Gastroenterología y Hepatología. Unidad de Endoscopias. Hospital Universitario Puerta De Hierro.
    Majadahonda, Madrid 28222, Spain
  • Servicio de Gastroenterología y Hepatología. Hospital Universitario San Agustín.
    Avilés, Principality of Asturias 33401, Spain
  • Servicio de Aparato Digestivo. Hospital Universitario de Cabueñes
    Oviedo, Principality of Asturias 33011, Spain
08

References and documents

Publications

  • Majano Diaz L, Rodriguez de Santiago E, Nunez Rodriguez H, Corte DP, de Jorge Turrion MA, Pellise M, Ocon JM, Pons FR, Santiago Garcia J, Alonso EB, Escaja CR, Santos Rodriguez A, Canete Ruiz A, Muriel A, Zamora J, Garcia BP, Carbonell SP, Garcia Garcia de Paredes A, Garrido Gomez E, Lopez Cardona J, Duran SL, Aicart-Ramos M, Lalastra CS, Angel Rodriguez Gandia M, Garcia de la Filia I, Aldehuelo RS, Hernandez ET, Martinez Sanchez A, Mateos Munoz B, Martinez Gonzalez J, Ortega JD, de la Fuente Briongos E, Redondo PD, Cano CC, Alvarez LP, Pieter CEC, Remizova MO, Gonzalez Silva I, Ferrer Blanco A, Claros LS, Tejedor-Tejada J, Jimenez Jurado A, Mazzola VKC, Cabal IB, Leoz D, Rivas E, Calvo A, Herreros-de-Tejada A, de Frutos Rosa D, Gomez FV, Gutierrez Landaluce P, Colomet RM, Diez PF, Blanco Garcia L, Castano Fernandez O, Ruiz Zorrilla Lopez R, Lorenzo MEM, Lopez Fernandez E, Sierra Morales M, Garcia Centeno P, Maestro Prada I, Vazquez-Sequeiros E, Albillos Martinez A; Mucosal Resection and Third-Space Endoscopy SEED Working Group. Temporary interruption versus maintenance of anticoagulation in polypectomy of colorectal lesions: study protocol for a multicentre randomised non-inferiority clinical trial POLYPHEM. BMJ Open. 2026 Mar 30;16(3):e111695. doi: 10.1136/bmjopen-2025-111695. PubMed 41916623 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Nov 2026, 25 months after the start.

Of 92 non-industry phase 4 interventional studies under Hemorrhage, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 25 months is below that.

Counting every sponsor, half of 96 studies reached it within 28 months; a quarter within 18 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 22, 2025
StartActual
Oct 18, 2024
Primary completionEst.
Nov 18, 2026
CompletionEst.
Dec 30, 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07185295
Lead sponsor
Outcomes'10
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Oct 18, 2024
Primary completion
Nov 18, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion